Why cervical cancer trial monitoring matters now
Cervical cancer has entered a new era of active clinical development. Pembrolizumab's approval in persistent/recurrent/metastatic disease and tisotumab vedotin's (TV) approval in second-line disease established two distinct treatment mechanisms. The current generation of trials is building on both. The live trial data on this page shows how many are active and recruiting.
Key areas driving new trial registrations:
- Pembrolizumab + TV combinations — testing synergy between checkpoint and TF-targeted ADC
- Next-generation ADCs targeting Tissue Factor (TF) and other cervical cancer antigens
- HPV-specific T cell receptor (TCR) therapies and cancer vaccines
- Neoadjuvant immunotherapy in locally advanced cervical cancer (a rapidly growing segment)
- HER2-targeted agents in HER2-amplified cervical cancer
- Novel VEGF combinations following bevacizumab's established role
Get daily cervical cancer trial digest
free plan, no credit card required. Monitor the cervical cancer trial landscape automatically.
Start Free — No Credit CardActive Phase 2/3 cervical cancer trials (2026)
Key Phase 3 and pivotal studies in cervical cancer currently recruiting or in startup:
| NCT ID | Trial / Agent | Sponsor | Status |
|---|---|---|---|
| NCT07216703 | Sacituzumab tirumotecan (MK-2870) + pembrolizumab in 1L/2L cervical cancer | Merck Sharp & Dohme | Recruiting |
| NCT06459180 | Sacituzumab tirumotecan monotherapy vs chemotherapy in recurrent cervical cancer | Merck Sharp & Dohme | Active, Not Recruiting |
| NCT06079671 | Volrustomig (CTLA-4/PD-L1 bispecific) in high-risk locally advanced cervical cancer | AstraZeneca | Recruiting |
| NCT07418749 | SHR-A2102 vs investigator's choice chemotherapy in recurrent/metastatic cervical cancer | Suzhou Suncadia | Recruiting |
| NCT07392060 | WX390 + toripalimab vs investigator's choice in cervical cancer | Shanghai Jiatan Pharmatech | Not Yet Recruiting |
| NCT07061977 | Induction pembrolizumab + chemotherapy followed by pembrolizumab before/after CRT | National Cancer Institute | Recruiting |
| NCT07400536 | Cadonilimab (PD-1+CTLA-4) + chemoradiation in locally advanced cervical cancer | Union Hospital, Tongji Medical College | Recruiting |
| NCT05581121 | Para-aortic lymphadenectomy in locally advanced cervical cancer (PARALA) | Institut Claudius Regaud | Recruiting |
What we monitor for cervical cancer
Configure your cervical cancer profile with the following options:
- Condition keywords: "cervical cancer", "cervical carcinoma", "HPV-positive cancer", "squamous cell carcinoma cervix", "adenocarcinoma cervix"
- Phase filter: Phase 1 for early pipeline, Phase 2/3 for registration-enabling and combination trials
- Sponsor filter: Industry-sponsored only, or all including NCI cooperative group trials
- Status filter: Recruiting only, or all active studies
The cervical cancer treatment landscape in 2026
Tisotumab vedotin follow-on combinations
Tisotumab vedotin's approval validated Tissue Factor as a clinically actionable target in cervical cancer. The innovaTV program is now exploring TV + pembrolizumab, TV + carboplatin, and TV + anti-VEGF combinations in both earlier lines and as maintenance. Competitor TF-targeted programs from other companies are also entering the clinical stage. Tracking these registrations maps the competitive landscape for TF-directed therapy.
HPV-targeted immunotherapy
Cervical cancer's HPV etiology makes it an ideal target for virus-directed immunotherapy. Multiple programs are developing TCR therapies targeting HPV E6 and E7 epitopes, therapeutic vaccines, and engineered T cell products. Several Phase 1/2 trials of HPV-specific cell therapy opened in 2025 and are recruiting at academic centers. This is one of the most distinctive features of cervical cancer clinical development compared to other solid tumors.
Neoadjuvant and organ-preservation approaches
Locally advanced cervical cancer has traditionally been treated with concurrent chemoradiation. A new generation of trials is testing neoadjuvant chemotherapy or immunotherapy before definitive CRT, with the goal of improving response rates and potentially enabling organ-preserving surgery. Phase 3 trial NCT07061977 is testing induction pembrolizumab + chemotherapy in this setting.
Global access and low-resource setting trials
Cervical cancer disproportionately affects women in low- and middle-income countries. Trials examining oral chemotherapy options, single-agent immunotherapy for resource-limited settings, and alternative RT schedules represent a unique component of the cervical cancer trial landscape that is often missed by conventional monitoring approaches.
Who uses cervical cancer trial monitoring
Gynecologic oncology BD teams
Companies developing assets in cervical cancer monitor competitor trial registrations to map the competitive landscape for TF-directed, HER2-directed, and immunotherapy approaches in this indication.
Radiation oncologists and gynecologic surgeons
Specialists treating locally advanced cervical cancer track neoadjuvant and concurrent therapy trial registrations to identify protocols potentially applicable to their patient populations and to understand emerging treatment algorithms.
Global health organizations and patient advocates
Organizations focused on cervical cancer elimination — WHO's 90-70-90 targets — monitor treatment and prevention trial activity to stay current on advances relevant to their advocacy and policy work.
Ready to automate your cervical cancer trial monitoring?
free plan — no credit card required. Setup takes under 2 minutes.
Get the Free DigestFrequently asked questions
Does this cover HPV-positive oropharyngeal cancer as well?
Not by default, but you can add keywords like "HPV-positive head and neck cancer" or "oropharyngeal squamous cell carcinoma" to a separate profile. On the Starter plan ($49/month), you can save up to 3 searches, each feeding the same daily digest.
How current is the cervical cancer trial data?
Our pipeline fetches from ClinicalTrials.gov every morning. Studies posted or updated in the preceding 24 hours appear in that day's digest.
What DataLookout adds to ClinicalTrials.gov
ClinicalTrials.gov RSS feeds tell you that a study record was updated. DataLookout compares each record against the previous day across 13 tracked fields and tells you which one changed, with the old and new values, for every Cervical Cancer trial on your watchlist. Each change is classified as critical, notable, or minor, so a trial flipping from recruiting to suspended does not read the same as a contact-details edit.
721 active trials, 389 recruiting.
Industry sponsors run 126 of these trials. The rest are run by universities, hospitals, government bodies and other non-commercial sponsors. The table below lists the 5 largest of 100.
| Top industry sponsor | Active trials |
|---|---|
| AstraZeneca | 5 |
| Merck (MSD) | 5 |
| Pfizer | 4 |
| Eli Lilly and Company | 3 |
| Shanghai Bovax Biotechnology Co., Ltd. | 3 |
| Trial | Status | Latest tracked change | Seen |
|---|---|---|---|
| A Study of Sofe-M in Participants With Selected Advanced Solid Tumors NCT06400472 | Recruiting | Interventions modified | 2026-09-05 |
| C-3002: Enhancing Cervical Cancer Screening Access and Follow-up Care at… NCT07520188 | Not Yet Recruiting | Completion pushed: 2027-05 → 2028-03-31 | 2026-09-02 |
| Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of… NCT04140526 | Active, Not Recruiting | Primary completion pushed: 2026-06-30 → 2026-12-31 | 2026-09-15 |
| Pembrolizumab and Lenvatinib in Advanced Cervical Cancer NCT04865887 | Recruiting | Completion pushed: 2026-07 → 2028-07 | 2026-09-11 |
| Hypofractionated Radiotherapy for the Treatment of Cervical or Endometrial… NCT05139368 | Active, Not Recruiting | Results posted: 2026-09-04 | 2026-09-05 |
Each trial page shows every change DataLookout has recorded for that trial.
DataLookout checks ClinicalTrials.gov every day and records what changed on each trial: status, enrollment, phase, primary endpoint, completion dates, sites, sponsor, and the stated reason a trial stopped. Add a sponsor or a disease to your watchlist, or save any search, and the changes arrive in a daily or weekly email digest.
Free, $0 forever: 1 sponsor + 1 disease watchlist, 1 saved search in your email digest, track up to 5 individual trials, daily change detection, Trials at Risk (top trial). No credit card.
Starter, $49/month: 3 sponsor + 3 disease watchlists, 3 saved searches in your email digest, track up to 25 individual trials, full Trials at Risk list and landscape reports.
Pro, $149/month: unlimited sponsor and disease watchlists, unlimited saved searches, track unlimited individual trials, CSV export, priority email support.